Royalty Pharma plc operates as the largest buyer of biopharmaceutical royalties and a major funder of innovation in the global life sciences industry. The company's business model centers on acquiring royalty interests in approved or late-stage development biopharmaceutical products. It generates revenue by collecting a percentage of the top-line sales from these therapies, which are marketed by leading global pharmaceutical companies. Royalty Pharma funds innovation both indirectly, by purchasing existing royalties from original innovators like academic institutions, research hospitals, and non-profits, and directly, by partnering with biotechnology and pharmaceutical companies to co-fund late-stage clinical trials and new product launches.
The company's extensive portfolio includes royalty interests in over 35 commercial products and numerous development-stage candidates. These therapies address a wide range of therapeutic areas, including rare diseases, oncology, neuroscience, infectious diseases, hematology, and diabetes. Notable products in its portfolio have included blockbuster drugs such as Humira, Imbruvica, Lyrica, and Xtandi. By providing a non-dilutive source of capital, Royalty Pharma plays a critical role in the biopharmaceutical ecosystem, enabling innovators to monetize their intellectual property and reinvest in further research and development. The company operates primarily in the United States but holds interests in products marketed globally.
